Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: María Cappiello (principal investigator)
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Sebastian Ferretti (principal investigator)
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· Phase 3· Eli Lilly and Company· Source
Contact: Florencia Garavelli (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: María Cappiello (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: María Cappiello (principal investigator)
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175· Phase 2· Eli Lilly and Company· Source
Contact: Dario Tavolini (principal investigator)
Active, not recruiting
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Hoffmann-La Roche· Source
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593· Phase 3· Eli Lilly and Company· Source
Contact: Dana Miralles (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: María Cappiello (principal investigator)
Recruiting
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
NCT07161258· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630· Phase 3· argenx· Source
Contact: Dario Tavolini, MD
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004· Phase 3· argenx· Source
Contact: Darío Tavolini, MD
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Contact: Dana Miralles (principal investigator)
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122· Phase 3· Eli Lilly and Company· Source
Contact: María Cappiello (principal investigator)
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580· Phase 3· Vor Biopharma· Source
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Contact: Dario Tavolini (principal investigator)
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320· Phase 3· H. Lundbeck A/S· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· Phase 3· Eli Lilly and Company· Source
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675· Phase 3· H. Lundbeck A/S· Source